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Abstract
Background: The Signal Transducer and Activator of Transcription 1 (STAT1) has traditionally
been regarded as a transmitter of interferon signaling and a pro-apoptotic tumour suppressor.
Recent data have identified new functions of STAT1 associated with tumourigenesis and resistance
to genotoxic stress, including ionizing radiation (IR) and chemotherapy. To investigate the
mechanisms contributing to the tumourigenic functions of STAT1, we performed a combined
transcriptomic-proteomic expressional analysis and found that STAT1 is associated with regulation
of energy metabolism with potential implication in the Warburg effect.
Methods: We generated a stable knockdown of STAT1 in the SCC61 human squamous cell
carcinoma cell line, established tumour xenografts in athymic mice, and compared transcriptomic
and proteomic profiles of STAT1 wild-type (WT) and knockdown (KD) untreated or irradiated (IR)
tumours. Transcriptional profiling was based on Affymetrix Human GeneChip® Gene 1.0 ST
microarrays. Proteomes were determined from the tandem mass spectrometry (MS/MS) data by
searching against the human subset of the UniProt database. Data were analysed using Significance
Analysis of Microarrays for ribonucleic acid and Visualize software for proteins. Functional analysis
was performed with Ingenuity Pathway Analysis with statistical significance measured by Fisher's
exact test.
Results: Knockdown of STAT1 led to significant growth suppression in untreated tumours and
radio sensitization of irradiated tumours. These changes were accompanied by alterations in the
expression of genes and proteins of glycolysis/gluconeogenesis (GG), the citrate cycle (CC) and
oxidative phosphorylation (OP). Of these pathways, GG had the most concordant changes in gene
and protein expression and demonstrated a STAT1-dependent expression of genes and proteins
consistent with tumour-specific glycolysis. In addition, IR drastically suppressed the GG pathway in
STAT1 KD tumours without significant change in STAT1 WT tumours.
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Conclusion: Our results identify a previously uncharacterized function of STAT1 in tumours:
expressional regulation of genes encoding proteins involved in glycolysis, the citrate cycle and
mitochondrial oxidative phosphorylation, with predominant regulation of glycolytic genes. STAT1-
dependent expressional regulation of glycolysis suggests a potential role for STAT1 as a
transcriptional modulator of genes responsible for the Warburg effect.
Background
Signal Transducer and Activator of Transcription 1
(STAT1) is the major transcriptional mediator of inter-
feron (IFN)-induced signaling for Type I (IFNα and IFNβ)
and Type II (IFNγ) interferons. While STAT1 has tradition-
ally been regarded as pro-apoptotic and tumour-suppress-
ing [1,2], we previously demonstrated that over-
expression of the STAT1 pathway confers radio resistance
and IFN-resistance [3-5]. Consistent with our observa-
tions are recent reports demonstrating that constitutive
over-expression of STAT1 and STAT1-dependent genes is
associated with protection of tumour cells from genotoxic
stress following treatment with fludarabine [6], doxoru-
bicin [7], cisplatin [8] and the combination of ionizing
radiation (IR) and doxorubicin [9,10].
To investigate the mechanisms by which STAT1 confers an
aggressive tumour phenotype, we characterized the down-
stream pathways regulated by STAT1. To this end, we gen-
erated a stable STAT1 knockdown (KD) in SCC61, a
clinically derived squamous cell carcinoma cell line [3,4],
and studied the effect of STAT1 KD on tumour growth and
response to IR in vivo. We then used a shotgun proteomic
approach, coupled with gene array analysis, to identify
proteins and genes differentially expressed in wild-type
(WT) and KD untreated or irradiated tumours. Our results
demonstrate that STAT1 modulates the expression of
genes encoding proteins involved in glycolysis/gluconeo-
genesis (GG), oxidative phosphorylation (OP), and the
citrate cycle (CC) and protects against IR-induced sup-
pression of genes and proteins belonging to these path-
ways. Thus, we report that a previously uncharacterized
role of STAT1 in regulating the expression of genes
involved in energy metabolism may mediate enhanced
tumour growth and radio resistance. Our results are con-
sistent with Warburg's finding that tumour cells utilize
glycolysis as the main pathway of energy metabolism even
in the presence of oxygen [11] and suggest that STAT1 is
involved in the transcriptional regulation of the Warburg
effect in tumour cells.
Methods
Cell culture and tumour model
The SCC61 human squamous cell carcinoma cell line was
stably transfected with a control vector (SCC61 STAT1
WT) or one expressing a short hairpin ribonucleic acid
(RNA) to STAT1 (SCC61 STAT1 KD) and maintained as
previously described [4]. Tumour xenografts were estab-
lished by a subcutaneous injection of 107 cells in 100 μL
of phosphate buffered saline into the right hind limbs of
6-week-old female athymic mice (FCRI-Taconic). When
tumours reached an average size of 160 mm3, ionizing
radiation was delivered in 5 Gy fractions over six consec-
utive days (total 30 Gy) using a Philips RT 250 X-ray gen-
erator with a dose rate of 1.65 Gy/min. Tumour volumes
of untreated control (C) and IR tumours were determined
by direct measurement with calipers and calculated using
the formula volume = length × width × depth/2.
Tumour data represent the mean tumour volume ± stand-
ard error of mean (SEM). Each point summarizes data
from four to nine animals (WT/C: 4; KD/C: 5; WT/IR: 7;
KD/IR: 9). Given that stable KD of STAT1 in nu61 resulted
in tumour growth suppression and radio sensitization [4],
we used 1-tailed Student's t-tests to test the null hypothe-
sis of equal mean tumour volume between STAT1 WT and
KD tumours for untreated and irradiated conditions.
When tumour volume reached 1000 mm3, mice were
euthanized by using CO2 followed by cervical dislocation.
Tumours were excised, snap-frozen in liquid nitrogen,
and stored at -80°C until RNA and protein extraction. All
animal experiments were conducted in accordance with
institutional guidelines at The University of Chicago.
Gene expression data collection and analysis
Frozen tumour xenografts were sectioned into pieces
approximately 5 mm3 in size and soaked overnight in
RNAlater®-ICE solution (Applied Biosystems-Ambion).
Samples were spun, washed in RNeasy Lysis Buffer (RLT)
buffer (QIAGEN), and homogenized on ice using a
mechanical glass-Teflon homogenizer set at 3000 rpm.
Subsequent purification was performed using TRIzol rea-
gent (Invitrogen Life Sciences) as previously described
[12]. The quality of samples was assessed using gel electro-
phoresis in 1.8% agarose and spectrophotometry, and
samples of high quality were transferred to the University
of Chicago Functional Genomics Facility for labelling and
hybridization with Affymetrix Human GeneChip® Gene
1.0 ST Arrays according to the manufacturer's protocol.
Each array was hybridized with a pooled sample normal-
ized to total RNA and consisting of RNA obtained from
three independent tumour xenografts. Retrieved data were
filtered using a multistep filtration method, which
involves the application of receiver operating characteris-BMC Medicine 2009, 7:68 http://www.biomedcentral.com/1741-7015/7/68
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tic analysis for the estimation of cutoff signal intensity val-
ues [13]. Only probe set identifiers (IDs) having gene
assignments (annotation date: 21 July 2008; Affymetrix)
were used for analysis. Subsequent analysis was based on
pair-wise comparisons (WT/C versus KD/C; WT/IR versus
KD/IR; WT/IR versus WT/C; KD/IR versus KD/C) of dupli-
cated arrays using Significance Analysis of Microarrays
(SAM) [14] version 3.02. Differentially expressed probe
set IDs were selected with a delta value that provided a
false discovery ratio of 0. A relative gene expression value
was calculated by normalization to the median expression
value for the gene across samples. Selected probe set IDs
were gene annotated and functionally designated using
Ingenuity Pathway Analysis (IPA; Ingenuity Systems, Inc).
Fisher's exact test was used to estimate the significance of
the incidence of different canonical pathways. This
method calculates the probability that the association
between an experimental gene set and a reference gene set
associated with a canonical pathway is due to random
chance. A P-value ≤ 0.05 was considered statistically sig-
nificant and indicated a nonrandom enrichment of an
experimental dataset by members of a specific pathway.
Protein expression data collection and analysis
Frozen tumour xenografts were sectioned into pieces
approximately 5 mm3 in size and homogenized on ice, as
described above, in a solution of 8 M urea, 18.2 mM dithi-
othreitol and 2% 3-[(3-Cholamidopropyl)dimethylam-
monio]-1-propanesulfonate (CHAPS). Samples were
spun and supernatants were collected. Peptide extraction
of pooled samples, normalized to total protein and con-
sisting of protein obtained from three to seven independ-
ent tumour xenografts, was performed as previously
described [15]. Peptides were subjected to LC/MS/MS
(liquid chromatography MS/MS) analysis using a liquid
trap quadruple from Thermo-Fisher coupled to a Surveyor
high-performance LC system equipped with a Micro AS
auto sampler. The instrument was interfaced with an
Aquasil, C18 PicoFrit capillary column (75 μm × 10 cm)
from New Objective. The mobile phases consisted of
0.1% formic acid containing 5% acetonitrile (A) and
0.1% formic acid in 95% acetonitrile (B), respectively. A
180-min linear gradient was used. The ions eluted from
the column were electro-sprayed at a voltage of 1.75 kV.
The proteome of each sample was determined from the
MS/MS data by searching against the human subset of the
UniProt database. Data were epitomized using Visualize
software (Dr Brian Halligan, Biotechnology and Bioengi-
neering Center, Medical College of Wisconsin, USA). The
false discovery rate for individual peptides was 0.05. Sin-
gle peptide hits with an x-score greater than 2.5 were
accepted in each independent run. In each pair-wise com-
parison, proteins that were not detected in both runs for
at least one sample were removed from further analysis.
Total ion current (TIC) was used as a means to quantify
the relative abundance of specific proteins between differ-
ent samples. Subsequent analysis was based on pair-wise
comparisons (WT/C versus KD/C; WT/IR versus KD/IR;
WT/IR versus WT/C; KD/IR versus KD/C) of duplicated
runs. Undetected TIC values were replaced by a value
equal to half the minimum value across all proteins. A rel-
ative protein expression value was calculated by normali-
zation to the median TIC value for the protein across
samples. Proteins were annotated and functionally desig-
nated using IPA. Fisher's exact test was used to estimate
the significance of the incidence of different canonical
pathways as described above.
Combined expressional analysis of overlapping pathways
To identify the pathways that mutually represented differ-
entially expressed genes and proteins, a Fisher's exact test
P-value ≤ 0.1 was considered significant. To assess the role
of STAT1 in the expression of each energy pathway (GG,
OP, CC), all of the genes and proteins belonging to the
pathway that were differentially expressed in at least one
comparative analysis were combined into a pathway set.
Genes not present in the set, but corresponding to differ-
entially expressed proteins, were subsequently added to
the pathway set. Multiple probe set IDs for a given gene
were averaged to obtain a representative expression value
for the gene.
Results
Knockdown of STAT1 in SCC61 tumour xenografts leads 
to growth suppression and radio sensitization
We previously demonstrated that stable KD of STAT1 in
nu61, a radioresistant derivative of the SCC61 tumour cell
line, led to decreased tumour growth and sensitization to
IR [4]. Here we hypothesized that stable KD of STAT1 in
SCC61 would also suppress tumour growth and cause
radio sensitization of SCC61. Indeed, KD of STAT1 in
untreated tumours led to a significant (t-test; P = 0.050)
2.7-fold suppression of tumour volume at day 40 relative
to STAT1 WT tumours (Figure 1). A comparison of irradi-
ated STAT1 WT and KD tumours demonstrated even larger
differences. KD of STAT1 in irradiated tumours signifi-
cantly (t-test; P = 0.017) suppressed tumour volume at day
68 by 6.5-fold (Figure 1). These results demonstrate that
KD of STAT1 in SCC61, a clinically derived tumour cell
line not subjected to any experimental selection, leads to
in vivo tumour growth suppression and radio sensitization
similar to that observed previously in nu61.
Identification of downstream functions of STAT1 using 
combined transcriptomic-proteomic expressional analysis
Using a combination of shotgun proteomics and tran-
scriptional profiling, we investigated the downstream
expressional changes associated with KD of STAT1 [16-
18]. Protein samples were subjected to LC/MS/MS peptide
analysis and RNA samples were hybridized with Affyme-BMC Medicine 2009, 7:68 http://www.biomedcentral.com/1741-7015/7/68
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trix exon-based arrays (see Methods and GEO accession
number GSE15845). Differentially expressed genes and
proteins were functionally annotated using IPA as
described [19,20] (Figure 2A).
We compared gene and protein expression profiles of
untreated STAT1 WT and KD tumours and identified the
differential expression of 92 genes and 266 proteins (Fig-
ure 2B; Additional files 1 and 2). Functional analysis of
differentially expressed genes and proteins identified a
significant overlap between transcriptomic and proteomic
approaches. We compared all significantly represented
pathways (see Methods) from gene and protein expres-
sion patterns and identified six overlapping pathways
(Figure 2C; Table 1). Notably, four of the six overlapping
pathways (OP, CC, pyruvate metabolism and GG) were
associated with energy metabolism. These results show
that functional mapping of transcriptomic and proteomic
data identifies genes and proteins associated with overlap-
ping functions, which is consistent with other reports
[21]. These results also demonstrate that growth suppres-
sion of SCC61 tumours caused by KD of STAT1 (see Figure
1) is associated with alterations in the expression of genes
and proteins involved in energy metabolism (see Table 1).
STAT1 modulates the expression of genes encoding 
proteins involved in glycolysis, oxidative phosphorylation 
and the citrate cycle
To characterize the role of STAT1 in the expressional regu-
lation of energy metabolic pathways, we examined the
expression of genes and proteins involved in GG, the CC
and OP because these pathways were jointly represented
in both the transcriptomic and proteomic analysis (see
Table 1). We performed pair-wise comparisons of STAT1
WT and KD tumours for untreated and irradiated condi-
tions and identified differentially expressed genes and
proteins belonging to the GG, CC and OP pathways. We
compiled differentially expressed genes and proteins (see
Methods; Additional file 3) to identify gene-protein pairs
regulated by STAT1 in the same manner (either up- or
down-regulated). This analysis identified 22 enzymes that
were similarly regulated at the gene and protein level by
STAT1 in at least one comparative analysis (Table 2). Six-
teen of the 22 gene-protein pairs (72.7%) were associated
with GG. The two CC enzymes identified in this analysis
and up-regulated by STAT1 produce reduced forms of the
coenzymes nicotinamide adenine dinucleotide (NADH:
malate dehydrogenase) and flavin adenine dinucleotide
(FADH2: succinate dehydrogenase), which are electron
donors in OP. In addition, three subunits of the soluble
catalytic core of mitochondrial adenosine triphosphate
(ATP) synthase (ATP5A1, ATP5B and ATP5O) were up-
regulated in STAT1 WT relative to KD tumours. Among
the 22 gene-protein pairs, the GG pathway was signifi-
cantly (2-sided Chi-square test; P = 0.030) more repre-
sented than the OP and CC pathways. These data
demonstrate that STAT1 is associated with regulation of
the expression of genes encoding proteins involved in
energy metabolic pathways, with the majority of identi-
fied molecules involved in glycolysis.
STAT1 protects tumours from IR-induced suppression of 
energy pathways
Based on our previous finding, that IR increases the
expression of STAT1 and STAT1-dependent genes in sev-
eral tumour types [4], and our current data, showing that
STAT1 regulates the expression of energy metabolic path-
ways, we hypothesized that STAT1 protects energy meta-
bolic pathways from IR-induced insult. We found that
STAT1 WT tumours demonstrated significant protection
(t-test; P < 0.0001) from IR-induced suppression of energy
pathways relative to STAT1 KD tumours (Figure 3A and
Additional file 4). The GG pathway demonstrated the
greatest protection from IR-induced suppression and
showed no significant change in STAT1 WT tumours (Fig-
Knockdown of STAT1 in SCC61 causes tumour growth sup- pression and radio sensitization Figure 1
Knockdown of STAT1 in SCC61 causes tumour 
growth suppression and radio sensitization. In 
untreated tumours, STAT1 [Signal Transducer and Activator 
of Transcription 1] knockdown (KD/C; white diamond) sig-
nificantly reduced day 40 tumour volume by 2.7-fold com-
pared to a control-vector transfected STAT1 wild-type (WT/
C; black diamond) (mean ± standard error of mean [SEM] 
[mm3]: WT/C = 1154 ± 404, KD/C = 427 ± 130; Student's t-
test P = 0.050). Ionizing radiation (IR) was delivered in 5 Gy 
fractions on days 0-5 (total 30 Gy). In irradiated tumours, 
KD of STAT1 (KD/IR; white triangle) significantly suppressed 
day 68 tumour volume by 6.5-fold compared to that of a 
STAT1 WT tumour (WT/IR; black triangle) (mean ± SEM 
[mm3]: WT/IR = 738 ± 232, KD/IR = 114 ± 21.2; Student's t-
test P = 0.017). Point, mean tumour volume; error bars, SEM. 
Tumour volumes are shown on a semi-log scale.BMC Medicine 2009, 7:68 http://www.biomedcentral.com/1741-7015/7/68
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ure 3A). Importantly, the STAT1 pathway [3,5] was signif-
icantly (t-test; P = 7.44e-5) up-regulated 3.8-fold in STAT1
WT relative to KD tumours (Figure 3B). These results dem-
onstrate a direct relationship between STAT1 pathway
expression and protection of tumour cells from IR-
induced suppression of energy pathways and suggest that
the survival of irradiated tumour clones (see Figure 1)
may be connected with the STAT1-dependent protection
of energy pathways.
Discussion
Utilizing a transcriptomic-proteomic approach together
with functional analysis, we report that STAT1 is associ-
ated with expression of genes and proteins of energy met-
abolic pathways including glycolysis, the citrate cycle and
Combined transcriptomic-proteomic analysis for identification of STAT1-dependent functions Figure 2
Combined transcriptomic-proteomic analysis for identification of STAT1-dependent functions. (A) Outline of 
transcriptomic-proteomic approach coupled with functional analysis for the identification of STAT1 [Signal Transducer and 
Activator of Transcription 1]-dependent molecules and functions. (B) Expressional clustering of differentially expressed genes 
(92) and proteins (266) in untreated SCC61 STAT1 wild-type and knockdown tumours: red, up-regulated; blue, down-regu-
lated. See Additional files 1 and 2 for further details. (C) Venn diagram of all significantly represented pathways on both the 
transcriptional and translational level. Eleven pathways were uniquely represented among differentially expressed genes, while 
34 pathways were uniquely represented among differentially expressed proteins. Six pathways were jointly represented among 
differentially expressed molecules, and four of these were associated with energy metabolism (see Table 1 for further details).
Table 1: Pathways mutually represented by differentially expressed Signal Transducer and Activator of Transcription 1 (STAT1)-
dependent genes and proteins.
Pathway P-value* (gene) P-value* (protein)
Oxidative phosphorylation 0.00251 0.0955
Citrate cycle 0.00741 0.0182
Urea cycle and metabolism of amino groups 0.00794 0.0224
Pyruvate metabolism 0.0380 0.000151
Nitric oxide signaling in the cardiovascular system 0.0389 0.0245
Glycolysis/gluconeogenesis 0.0589 0.000000000776
*P-value, Fisher's exact testBMC Medicine 2009, 7:68 http://www.biomedcentral.com/1741-7015/7/68
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Table 2: Enzymes co-regulated at the gene and protein level by Signal Transducer and Activator of Transcription 1 (STAT1)
Pathway Gene Symbol Description Function
GG ALDH1A1 Aldehyde dehydrogenase 1 family, member A1 Oxidation of acetaldehyde to acetate
GG ALDH2 Aldehyde dehydrogenase 2 family (mitochondrial) Oxidation of acetaldehyde to acetate
GG ALDOA Aldolase A, fructose-bisphosphate Cleavage of fructose 1,6-bisphosphate into glyceraldehyde 3-
phosphate and dihydroxyacetone phosphate
GG ENO1 Enolase 1, (alpha) Dehydration of 2-phosphoglycerate to phosphoenolpyruvate
GG ENO2 Enolase 2 (gamma, neuronal) Dehydration of 2-phosphoglycerate to phosphoenolpyruvate
GG ENO3 Enolase 3 (beta, muscle) Dehydration of 2-phosphoglycerate to phosphoenolpyruvate
GG GAPDH Glyceraldehyde-3-phosphate dehydrogenase Oxidation and phosphorylation of glyceraldehyde 3-phosphate 
to 1,3-bisphosphoglycerate with reduction of NAD+ to NADH
GG GPI Glucose phosphate isomerase Conversion of glucose 6-phosphate to fructose 6-phosphate
GG LDHA Lactate dehydrogenase A Reduction of pyruvate to lactate with oxidation of NADH to 
NAD+
GG LDHAL6B Lactate dehydrogenase A-like 6B Reduction of pyruvate to lactate with oxidation of NADH to 
NAD+
GG LDHB Lactate dehydrogenase B Reduction of pyruvate to lactate with oxidation of NADH to 
NAD+
GG PGAM1 Phosphoglycerate mutase 1 (brain) Conversion of 3-phosphoglycerate to 2-phosphoglycerate
GG PGK1 Phosphoglycerate kinase 1 Phosphoryl transfer from 1,3-bisphosphoglycerate to ADP with 
formation of 3-phosphoglycerate and ATP
GG PGM1 Phosphoglucomutase 1 Interconversion of glucose 1-phosphate and glucose 6-
phosphate
GG PKM2 Pyruvate kinase type 2, muscle Phosphoryl transfer from phosphoenolpyruvate to ADP with 
formation of pyruvate and ATP
GG TPI1 Triosephosphate isomerase 1 Interconversion of dihydroxyacetone phosphate and 
glyceraldehyde 3-phosphate
OP ATP5A1 ATP synthase, H+ transporting, mitochondrial F1 
complex, alpha subunit 1, cardiac muscle
Synthesis of ATP from ADP and inorganic phosphate
OP ATP5O ATP synthase, H+ transporting, mitochondrial F1 
complex, O subunit
Synthesis of ATP from ADP and inorganic phosphate
OP ATP5B ATP synthase, H+ transporting, mitochondrial F1 
complex, beta polypeptide
Synthesis of ATP from ADP and inorganic phosphate
OP COX4I1 Cytochrome c oxidase subunit IV isoform 1 Oxidation of cytochrome C with reduction of O2 to H2O
OP/CC SDHA Succinate dehydrogenase complex, subunit A, 
flavoprotein (Fp)
Oxidation of succinate to fumarate with reduction of FAD+ to 
FADH2
CC MDH2 Malate dehydrogenase 2, NAD (mitochondrial) Oxidation of malate to oxaloacetate with reduction of NAD+ 
to NADH
GG, glycolysis/gluconeogenesis; OP, oxidative phosphorylation; CC, citrate cycleBMC Medicine 2009, 7:68 http://www.biomedcentral.com/1741-7015/7/68
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oxidative phosphorylation. The STAT1-dependent expres-
sion of glycolysis was particularly evident, as 16 enzymes
in this pathway were identified in our analysis, with the
majority of them up-regulated in STAT1 WT relative to KD
tumours (see Table 2 and Figure 4). Given that glycolysis
is considered the predominant energy-producing pathway
in tumour cells [11] and that high glycolytic flux in
tumours has been associated with poor prognosis [22],
our data suggest that the tumour-promoting functions of
STAT1, described here and reported previously [4], are, at
least in part, associated with transcriptional regulation of
glycolysis. Further investigation in order to assess the
direct metabolic effects of STAT1 on glycolysis will be nec-
essary. Nevertheless, two key enzymes responsible for the
maintenance of tumour glycolysis in aerobic conditions -
lactate dehydrogenase A (LDHA) [23] and pyruvate kinase
type M2 (PKM2) [24] - were among those identified in
our analysis as up-regulated by STAT1 at both the gene
and protein level (see Table 2 and Figure 4).
These results are consistent with Warburg's finding that
glycolysis is the primary mechanism of energy production
in tumour cells compared to oxidative phosphorylation
[11]. Warburg demonstrated that even in the presence of
ample oxygen, tumour cell glycolysis leads to lactate pro-
duction, similar to that observed in normal cells under
anaerobic conditions, without significant involvement of
OP (see Figure 4). The molecular mechanisms of this phe-
nomenon, now known as the 'Warburg effect', are cur-
rently under extensive investigation. Several oncogenes
and tumour suppressor genes have recently been sug-
gested as regulators of the Warburg effect. Among them
are TP53 [25], RAS [26], AKT [27], STAT3 [28], and several
other candidates (see [29-31] for review). Our results sug-
gest that STAT1-associated transcriptional changes are
also involved in regulation of the Warburg effect in
tumour cells.
We also report here that ionizing radiation inhibits the
expression of genes encoding proteins involved in energy
metabolism (see Figure 3). We found that IR treatment
resulted in modest suppression of GG, CC and OP gene
and protein expression in STAT1 WT tumours. We also
reported previously [32] that a 10 Gy dose of IR led to the
down-regulation of energy-related genes including LDHA,
which is considered a key enzyme of tumour-specific gly-
colysis [23]. A recent report showed similar IR-induced
reductions in the expression of genes related to energy
metabolism in human melanoma cells [33]. However,
STAT1 KD tumours showed significantly decreased
expression of GG, CC and OP genes and proteins relative
to WT tumours, indicating that STAT1 is associated with
protecting GG, CC and OP expression following IR. Given
that STAT1 KD tumours were also significantly radio sen-
sitized compared to WT tumours in vivo (Figure 1), our
results suggests that a potential mechanism of tumour
radio sensitization through STAT1 suppression may be IR-
induced energy deprivation of proliferating tumour cells.
Thus, these results identify a previously uncharacterized
role of STAT1 in the expressional regulation of genes
encoding proteins involved in glycolysis as well as the cit-
rate cycle and oxidative phosphorylation (see Figure 4). In
addition, these data demonstrate the ability of STAT1 to
protect against IR-induced suppression of genes and pro-
teins belonging to energy-related pathways [32,33] which
may protect tumour cells from energy deprivation and
mediate radioresistance. Thus, changes in energy-related
metabolic pathways may provide growth advantages to
tumour cells and support aggressive tumour phenotypes,
and STAT1 may be a valuable target for antitumour ther-
apy directed towards energy depletion of proliferating
tumour cells.
Conclusion
We demonstrated that stable KD of STAT1 in the SCC61
human squamous cell carcinoma leads to growth suppres-
sion and radio sensitization of tumour xenografts. To
define the pathways involved in STAT1-dependent growth
and radioresistance, we used a combined transcriptomic-
STAT1 protects tumours from ionizing radiation-induced  decreases in the expression of energy metabolic pathways Figure 3
STAT1 protects tumours from ionizing radiation-
induced decreases in the expression of energy meta-
bolic pathways. (A) Changes in the expression of glycoly-
sis/gluconeogenesis (GG), citrate cycle (CC) and oxidative 
phosphorylation (OP) energy metabolic pathways in 
response to ionizing radiation(IR) treatment of STAT1 wild-
type (WT) and knockdown (KD) tumours. There was no sig-
nificant decrease in the expression of the GG pathway in 
STAT1 WT tumours in the response to IR (mean irradiated/
untreated ratio = 0.91; 95% confidence interval [0.77, 1.05]). 
P-values indicate significant differences (Student's 2-tailed t-
tests) between STAT1 WT and KD tumours. Points, mean 
value of the ratio of irradiated to untreated for the pathway; 
error bars, SEM. See Additional file 4 for further details. (B) 
Expressional clustering of the 24-gene STAT1 pathway in 
STAT1 KD and WT tumours indicates a significant 3.8-fold 
up-regulation of the STAT1 pathway (Student's 1-tailed t-
test; P = 7.44e-5). Relative expression values are in log2 scale: 
red, up-regulated; green, down-regulated.BMC Medicine 2009, 7:68 http://www.biomedcentral.com/1741-7015/7/68
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proteomic approach and found that STAT1 is responsible
for the expressional regulation of genes and proteins
involved in glycolysis, the citrate cycle and oxidative phos-
phorylation. However, the majority of genes and proteins
associated with STAT1 were involved in regulation of gly-
colysis, a pathway essential to proliferating tumour cells.
We conclude that on the transcriptional level, STAT1 con-
tributes to regulation of the Warburg effect, which reflects
the dependence of tumour cells on glycolysis as a major
pathway of energy production necessary for tumour
growth. Our results also demonstrate that STAT1 protects
energy pathways from radiation-induced transcriptional
suppression, which may in part explain the radio-protec-
tive functions of STAT1.
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Energy metabolic map of enzymes up-regulated on the transcriptional and translational levels by STAT1 Figure 4
Energy metabolic map of enzymes up-regulated on the transcriptional and translational levels by STAT1. The 
majority of enzymes belonged to the glycolytic pathway. The two citrate cycle enzymes produce reduced forms of the coen-
zymes nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2), which donate electrons in the oxi-
dative phosphorylation pathway. Also, three subunits of the catalytic core of mitochondrial adenosine triphosphate synthase 
(F1) were identified. Red, up-regulated by Signal Transducer and Activator of Transcription 1 (STAT1). See Table 2 for further 
details.BMC Medicine 2009, 7:68 http://www.biomedcentral.com/1741-7015/7/68
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